Category: News
-
New Technology for the Proteomic Age (Nature Publication)
A leader in protein-based diagnostic tests, Biodesix is improving the precision of applying personalized medicine by advancing beyond the exploration of genes
-
VeriStrat Test Passes Phase 3 Trial | Biodesix
Biodesix, a Boulder, CO-based company that develops molecular diagnostic tests, said today that it has passed a key clinical trial that shows its VeriStrat test can give physicians a better idea of what to do next after the first round of treatment for non-small cell lung cancer has failed.
-
Putting Lung Cancer in the Bullseye (Breakthroughs)
Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. She’s deep into researching targeted therapies for lung cancer so she can offer up better treatment options.
-
Biodesix Feels the Buzz at BIO2012 (FierceBiomarkers)
Paul Beresford, vice president of business development and strategic marketing at Biodesix, spoke to FierceBiomarkers ahead of his appearance on the BIO2012 panel “Commercialization of Personalized Medicine: Stakeholders’ Recipe For Success.” So what is Biodesix’s own recipe for success? Keeping it collaborative and seeking validation, he explains. Biodesix’s business model is based on two strands–clinical diagnostics and…
-
A Test to Go With It (GenomeWeb)
Personalized medicine promises to tailor treatments to patients’ diseases, so to determine whether a drug is suitable for a given patient, pharmaceutical companies are increasingly turning to companion diagnostic tests — tests that, by definition, are necessary to decide if a course of treatment is right for a particular patient. Many such companion tests…
-
The Burrill Report | Biodesix
Some of the fastest evolving tools for evaluating the molecular and genetic underpinnings of disease are proving difficult to wield. Despite their great potential, it has been difficult to translate data generated through genomics, proteomics, and metabolomics into actual improvements in patient care. In hopes of speeding that progress, The Institute of Medicine in March…
-
A Better Route for Diagnostics? (Drug Discovery & Development)
From the moment of its inception, the Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. Equally important are the mRNA transcripts that carry out the genome’s orders, the proteins they encode, and ultimately, the metabolites upon which they act. Today, thanks to rapid…
-
Advances in Personalized Medicine for Lung Cancer (Science Daily)
Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva. “A major goal of lung cancer treatment is to tailor the treatment to the individual,” says Dr Fiona Blackhall from The Christie…
-
Protein Test Found to Boost NSCLC Survival, Costs (MedPage Today)
This study found that choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer (NSCLC). The four- to six-week survival advantage held up in a sensitivity analysis involving 10,000 simulations. Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in…
-
Genetic Engineering News | Biodesix
The use of Biodesix’ predictive cancer therapy assay VeriStrat has been validated in a Phase III trial originally carried out to evaluate GlaxoSmithKline’s Tykerb®/Tyverb® (lapatinib) as an addition to Novartis’ Femara® (letrozole) in breast cancer patients. Data from the trial demonstrated that VeriStrat could be used to identify a group of patients with worse progression-free survival (PFS) when treated with Femara alone, independent of Her2…